Clinical trials: Primary Prevention of Cardiovascular Disease
Venous Thromboembolism
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily.
- Trial name
- NCT00657150
- Testing
- Enoxaparin, Dabigatran etexilate
- Where
- 108 sites in United States, Australia and 17 more
- Volunteers
- 2,055 people
- Sponsor
- Boehringer Ingelheim
Prevent Osteoporosis and Osteoporotic Fractures, Improve Quality of Life
BREAST CANCER AND EXERCISE
A Finnish Breast Cancer Group Study (BREX 01-2004). A multicenter phase III open randomised trial of the efficacy of exercise in the prevention of long-term adverse effects of adjuvant treatments and breast cancer recurrences in…
- Conditions
- Prevent Osteoporosis and Osteoporotic Fractures, Improve Quality of Life, Improve Weight Control, and Muscular and Cardiovascular Fitness, Help the Patients to Return to Working Life
- Trial name
- BREX (NCT00639210)
- Testing
- supervised training
- Where
- Finland
- Volunteers
- 573 people
- Sponsor
- Finnish Breast Cancer Group
Stroke
Involvement of the Physician in Primary Prevention and Pre-hospital Management of Stroke
Stroke is a growing disease. It is the first pathology responsible for acquired handicap, the second of dementia and the second cause of death in the world.
- Trial name
- PREVENTION AVC (NCT03975218)
- Testing
- Patients With Stroke
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Peripheral Arterial Disease (PAD), Moderate Risk for Cardiovascular Disease (CVD)
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention
Non interventional study aimed to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index (ABI) not above 0.90 in subjects with a moderate risk of cardiovascular disease…
- Trial name
- PANDORA (NCT00689377)
- Where
- 331 sites in Belgium, France and 4 more
- Volunteers
- 9,000 people
- Sponsor
- AstraZeneca
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Variceal Bleeding, Cirrhosis
Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding
This study is performed to compare the efficacy and safety of EBL, propranolol, and EBL combined with propranolol in patients with medium or large varices.
- Trial name
- NCT00965900
- Testing
- Endoscopic band ligation, Propranolol, EBL+Propranolol
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Korea University
Obesity, Sedentary Lifestyle
The Healthy Options Feasibility Study
The investigators hypothesize that having health care providers other than physicians within a "Groupe de Médecine de Famille" conduct cardiovascular risk assessments and teach lifestyle interventions to primary prevention…
- Conditions
- Obesity, Sedentary Lifestyle, Dyslipidemia, Hypertension
- Trial name
- NCT00746460
- Testing
- CVD risk profile
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University
Hypercholesteremia
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
- Trial name
- NCT00347217
- Where
- 215 sites in Netherlands
- Volunteers
- 3,840 people
- Sponsor
- AstraZeneca
Febrile Neutropenia, Cancer
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
This international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for chemotherapy-induced febrile neutropenia (FN) who are receiving filgrastim biosimilar (EP2006) for…
- Conditions
- Febrile Neutropenia, Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- Monitor-GCSF (NCT01459653)
- Where
- 117 sites in Austria, Belgium and 10 more
- Volunteers
- 1,496 people
- Sponsor
- Sandoz
Cardiac Death
Reduction of Inappropriate Implantable Cardioverter Defibrillator (ICD) Therapies in Primary Prevention Patients
The purpose of this study is to determine efficacy of a dedicated programming concept for avoidance of inappropriate implantable cardioverter defibrillator (ICD) therapies in patient with primary prevention ICD indication.
- Trial name
- DECREASE (NCT01217528)
- Testing
- device settings for group A, Device settings for group B
- Where
- 34 sites in Germany
- Volunteers
- 543 people
- Sponsor
- Abbott Medical Devices
Hereditary Angioedema, HAE
Oral Berotralstat Expanded Access Program
This expanded access program will provide access to berotralstat for eligible participants with hereditary angioedema in the U.S.
- Conditions
- Hereditary Angioedema, HAE, Prophylaxis
- Trial name
- NCT04428632
- Testing
- Berotralstat
- Sponsor
- BioCryst Pharmaceuticals
Heart Failure, Anthracycline-induced Cardiac Toxicity
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused…
- Conditions
- Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD), Arterial Stiffness
- Trial name
- Alpaca (NCT07245069)
- Testing
- Dapagliflozin 10 mg
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana
Myocardial Infarction, Autonomic Dysfunction
The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction
Aims heart rate variability (HRV) assessment in patients with acute myocardial infarction who undergo primary percutaneous coronary intervention (PCI); measurement of HRV using a device approved for medical use in Europe…
- Trial name
- HeaRt-V-AMI (NCT05098977)
- Testing
- Heart rate variability measurement, Percutaneous coronary intervention
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Cardiovascular Disease
Medication Management and Culture of Safety
There will be no significant decrease in the use of low dose acetylsalicylic acid (ASA) therapy for primary prevention across the three intervention arms from baseline to completion of the project.
- Trial name
- MM (NCT01247454)
- Testing
- academic detailing, Electronic Health Record (EHR) prompt, EHR prompt and patient prompt
- Where
- United States
- Volunteers
- 7,000 people
- Sponsor
- University of Colorado, Denver
High Blood Pressure, Hypercholesterolemia
Cardiovascular Risk Factors And Intensive Dietary Counselling
The Intensive Dietary Counselling (IDC) intervention is a prevention and health promotion activity. It is being implemented by the Andalusian Health Service to reinforce basic intervention advice on healthy diet and exercise.
- Conditions
- High Blood Pressure, Hypercholesterolemia, Tobacco Smoking
- Trial name
- NCT02173600
- Testing
- Group-level Intensive dietary Counselling, Individual-level Intensive Dietary Counselling
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Andalusian Regional Ministry of Health
Cardiovascular Diseases, Overweight
Enhancing Mental and Physical Health of Women Veterans
Women Veterans are the fastest growing segment of VA users. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able…
- Conditions
- Cardiovascular Diseases, Overweight, Obesity, Smoking
- Trial name
- EMPOWER (NCT05050266)
- Testing
- EBQI, REP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- VA Office of Research and Development
Coronary Artery Disease, Coronary Artery Stenosis
Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention
There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve…
- Trial name
- NHIS (NCT06281041)
- Testing
- Antiplatelet Agents
- Where
- South Korea
- Volunteers
- 4,657 people
- Sponsor
- Samsung Medical Center
Lipoprotein(a)
Heart CT Imaging to Detect Early Coronary Artery Disease in First-Degree Relatives With High or Low Lipoprotein(a) Identified Through Family Screening
Lipoprotein(a), or Lp(a), is a type of cholesterol that can increase the risk of heart and blood vessel disease. Many people are unaware they have high Lp(a), since it is not routinely measured and usually causes no symptoms on…
- Trial name
- IMAGE-LPA (NCT06995183)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- E.S.stroes
Ischemic Stroke, Hemorrhagic Stroke
Improved Prevention of Stroke in Primary Care in Stockholm, Sweden (Förbättrad Prevention av Stroke)
Stroke is a devastating disease. The acute mortality in Sweden is 20 % and 25 % of all patients relapse. Secondary prevention is proven efficient but observational studies have shown that a number of patients are lost to follow…
- Conditions
- Ischemic Stroke, Hemorrhagic Stroke, TIA, Atrial Fibrillation
- Trial name
- NCT01942031
- Testing
- structured collegial feed back
- Where
- Sweden
- Volunteers
- 204 people
- Sponsor
- Karolinska Institutet
Sickle Cell Disease, Stroke
Stroke Prevention in Nigeria 2 Trial
The primary goal of this study is to complete a multicenter single-arm, type I hybrid trial to assess the effectiveness of hydroxyurea therapy for primary stroke prevention in high-risk children with sickle cell anemia (SCA)…
- Trial name
- SPRING-2 (NCT06526117)
- Testing
- Hydroxyurea
- Where
- 2 sites in Nigeria
- Volunteers
- 220 people
- Sponsor
- Vanderbilt University Medical Center